Faculty of Health Sciences, Oslo Metropolitan University, P.O. Box 4, St. Olavsplass, 0130, Oslo, Norway.
Norwegian National Advisory Unit on Familial Hypercholesterolemia, Oslo University Hospital Rikshospitalet, P.O. Box 4950, Nydalen, 0424, Oslo, Norway.
Lipids Health Dis. 2020 May 9;19(1):90. doi: 10.1186/s12944-020-01273-z.
The ever-increasing prevalence of obesity constitutes a major health problem worldwide. A subgroup of obese individuals has been described as "metabolically healthy obese" (MHO). In contrast to metabolically unhealthy obese (MUO), the MHO phenotype has a favorable risk profile. Despite this, the MHO phenotype is still sub-optimally characterized with respect to a comprehensive risk assessment. Our aim was to increase the understanding of metabolic alterations associated with healthy and unhealthy obesity.
In this cross-sectional study, men and women (18-70 years) with obesity (body mass index (BMI) ≥ 30 kg/m) or normal weight (NW) (BMI ≤ 25 kg/m) were classified with MHO (n = 9), MUO (n = 10) or NW (n = 11) according to weight, lipid profile and glycemic regulation. We characterized individuals by comprehensive metabolic profiling using a commercial available high-throughput proton NMR metabolomics platform. Plasma fatty acid profile, including short chain fatty acids, was measured using gas chromatography.
The concentrations of very low density lipoprotein (VLDL), intermediate density lipoprotein (IDL) and low density lipoprotein (LDL) subclasses were overall significantly higher, and high density lipoprotein (HDL) subclasses lower in MUO compared with MHO. VLDL and IDL subclasses were significantly lower and HDL subclasses were higher in NW compared with MHO. The concentration of isoleucine, leucine and valine was significantly higher in MUO compared with MHO, and the concentration phenylalanine was lower in NW subjects compared with MHO. The fatty acid profile in MHO was overall more favorable compared with MUO.
Comprehensive metabolic profiling supports that MHO subjects have intermediate-stage cardiovascular disease risk marker profile compared with NW and MUO subjects.
NCT01034436, Fatty acid quality and overweight (FO-study).
肥胖的发病率不断上升，已成为全球主要的健康问题。肥胖人群中存在一个亚组，被描述为“代谢健康型肥胖（MHO）”。与代谢不健康型肥胖（MUO）相比，MHO 表型具有较好的风险特征。尽管如此，在综合风险评估方面，MHO 表型的特征仍然不够完善。我们的目的是增加对与健康和不健康肥胖相关的代谢改变的理解。
在这项横断面研究中，根据体重、血脂谱和血糖调节情况，将 18-70 岁的男性和女性（肥胖者 BMI≥30kg/m，正常体重者 BMI≤25kg/m）分为 MHO（n=9）、MUO（n=10）或 NW（n=11）。使用商业高通量质子 NMR 代谢组学平台对个体进行全面的代谢特征分析。使用气相色谱法测量血浆脂肪酸谱，包括短链脂肪酸。
MUO 中极低密度脂蛋白（VLDL）、中间密度脂蛋白（IDL）和低密度脂蛋白（LDL）亚类的浓度总体显著升高，高密度脂蛋白（HDL）亚类的浓度显著降低。与 MHO 相比，NW 中 VLDL 和 IDL 亚类的浓度显著降低，HDL 亚类的浓度显著升高。MUO 中异亮氨酸、亮氨酸和缬氨酸的浓度显著高于 MHO，而 NW 中苯丙氨酸的浓度显著低于 MHO。与 MUO 相比，MHO 的脂肪酸谱总体更有利。
全面的代谢特征分析支持 MHO 患者与 NW 和 MUO 患者相比具有处于中间阶段的心血管疾病风险标志物特征。
NCT01034436，脂肪酸质量与超重（FO 研究）。
